And in the meantime we are developing our other products in the background.
We aren't a company that has yet to get FDA results, that have no income stream, or that is heavily reliant on loans to fund all the future trials we need.
This is the benefit of reaching this stage of development, where we are at break even. We are substantially derisked compared to most other small cap biotechs on the market.
Just gotta sit and be patient.
PNV - Banter and General Comments, page-5954
-
- There are more pages in this discussion • 6,118 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.37 |
Change
0.080(3.49%) |
Mkt cap ! $1.635B | |||
| Open | High | Low | Value | Volume |
| $2.35 | $2.44 | $2.31 | $4.848M | 2.032M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 31280 | $2.36 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.38 | 6793 | 3 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| PNV (ASX) Chart |